Literature DB >> 1360380

The allometric approach for interspecies scaling of pharmacokinetic parameters.

W A Ritschel1, N N Vachharajani, R D Johnson, A S Hussain.   

Abstract

A long standing problem in pharmacokinetics and toxicology is the extrapolation and correlation between results obtained in different animal species and man. Animal data may be scaled-up to predict PPs in man using the allometric approach. The allometric approach is empirical, but easy, and is based on the fact that the underlying physiological processes such as blood flow, heartbeat duration, breath duration etc. are essentially physical and related to B. This approach is generally applicable to compounds that are essentially renally excreted. For substances that are highly extracted by the liver, Cltot is a function of the LBF among various species. Based on the concept of neoteny, use of brain weight affords a more correct approach to the scaling of Cl(int) of low extraction ratio drugs. By using the invariant pharmacokinetic time, the superficial differences in concentration-time profiles due to chronological time among different species are removed. Finally, as Boxenbaum (1984) has said "parameters to be scaled, independent variables, and the mathematical relationships used in the scaling process are all at the discretion of the investigator. There are no proper or improper approaches; the only limitations are those imposed by the investigator."

Entities:  

Mesh:

Year:  1992        PMID: 1360380     DOI: 10.1016/0742-8413(92)90003-p

Source DB:  PubMed          Journal:  Comp Biochem Physiol C        ISSN: 0742-8413


  11 in total

1.  Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.

Authors:  Jie Zhao; Yanguang Cao; William J Jusko
Journal:  Pharm Res       Date:  2015-05-05       Impact factor: 4.200

Review 2.  Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity.

Authors:  Sihem Ait-Oudhia; Meric Ayse Ovacik; Donald E Mager
Journal:  MAbs       Date:  2016-09-23       Impact factor: 5.857

3.  A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse.

Authors:  M D McSweeney; T Wessler; L S L Price; E C Ciociola; L B Herity; J A Piscitelli; W C Zamboni; M G Forest; Y Cao; S K Lai
Journal:  J Control Release       Date:  2018-06-05       Impact factor: 9.776

Review 4.  The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development.

Authors:  D K Walker
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

5.  Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family.

Authors:  Matthew A Gregory; Michael Bobardt; Susan Obeid; Udayan Chatterji; Nigel J Coates; Teresa Foster; Philippe Gallay; Pieter Leyssen; Steven J Moss; Johan Neyts; Mohammad Nur-e-Alam; Jan Paeshuyse; Mahmood Piraee; Dipen Suthar; Tony Warneck; Ming-Qiang Zhang; Barrie Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2011-03-07       Impact factor: 5.191

6.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

7.  Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator.

Authors:  Venkata V Pavankuamr; C A Vinu; Ramesh Mullangi; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Jan-Mar       Impact factor: 2.441

8.  Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2.

Authors:  Weon Sup Lee; Sang Ryeol Shim; Seon Young Lee; Jin San Yoo; Sung Kweon Cho
Journal:  Drug Des Devel Ther       Date:  2018-03-08       Impact factor: 4.162

9.  Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infection.

Authors:  Adams Amantana; Yali Chen; Shanthakumar R Tyavanagimatt; Kevin F Jones; Robert Jordan; Jarasvech Chinsangaram; Tove C Bolken; Janet M Leeds; Dennis E Hruby
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.752

10.  New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.

Authors:  I H Bartelink; N Zhang; R J Keizer; N Strydom; P J Converse; K E Dooley; E L Nuermberger; R M Savic
Journal:  Clin Transl Sci       Date:  2017-05-31       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.